Impact of personalized cardiovascular disease risk estimates on physical activity-a randomized controlled trial

Diabetic Medicine

Volumn 28, Issue 3, 2011, Pages 363-372

  Price, H C ^a   Griffin, S J ^b   Holman, R R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Communication; Physical activity; Risk

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACCELEROMETRY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; LIFESTYLE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEX RATIO;

ADULT; AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 79851484861     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03212.x     Document Type: Article

References (37)

1. Gray J, ed. Vascular Disease Control Programme. London: Diabetes, Heart Disease and Stroke Prevention Project Advisory Group, 2006.
2. Davies M, Khunti K, Chauhan U, Stribling B, Goyder E, Farooqi A et al. The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management. London: UK National Screening Committee, 2008.
3. Price HC, Tucker L, Griffin SJ, Holman RR. The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2×2 factorial understanding risk trial. Cardiovasc Diabetol 2008; 7: 21.
4. Joint British Societies. JBS2: guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91: v1-v2.
5. Leventhal H, Leventhal E, Contrada R. Self-regulation, health and behaviour: a perceptual-cognitive approach. Psychol Health 1998; 13: 717-733.
6. Department of Health. Summary of Intelligence on Physical Activity. London: Department of Health, 2004.
7. Food Standards Agency. Nutrient and Food Based Guidelines for UK Institutions. London: Food Standards Agency, 2006.
8. Foster R, Marriott, HE. Alcohol consumption in the new millennium - weighing up the risks and benefits for our health. Nutr Bull 2006; 31: 286-331.
9. Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S et al. Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005; 28: 888-894.
10. ActiGraph. Website. Available at Last accessed 2 August 2010.
11. Coleman R, Stevens R, Holman R. Estimating cardiovascular disease risk for individuals with Type2 diabetes: the new UKPDS Risk Engine. Diabet Med 2007; 24: S56.
12. Anderson K, Odell P, Wilson P, Kannel W. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-298.
13. Freedson P, Melanson E, Sirard J. Calibration of the Computer Science and Applications Inc. accelerometer. Med Sci Sports Exerc 1998; 30: 777-781.
14. Ekelund U, Griffin S, Wareham N. Physical activity and metabolic risk in individuals with a family history of type2 diabetes. Diabetes Care 2007; 30: 337-342.
15. Bender R, Lange S. Adjusting for multiple testing-when and how? J Clin Epidemiol 2001; 54: 343-399.
16. Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
17. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
18. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30years of follow-up from the Framingham study. J Am Med Assoc 1987; 257: 2176-2180.
19. Sacks FM, Moyé LA, Davis BR, Cole TG, Rouleau JL, Nash DT et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998; 97: 1446-1452.
20. Wiesemann A, Ludt S, Szecsenyi J, Scheuermann W, Scheidt R. Cardiovascular risk factors and motivation for a healthy lifestyle in a German community-results of the GP-based Oestringen study. Patient Educ Couns 2004; 55: 40-47.
21. Marteau T, Kinmonth A, Thompson S, Pyke S. The psychological impact of cardiovascular screening and intervention in primary care: a problem of false reassurance? British Family Heart Study Group. Br J Gen Pract 1996; 46: 577-582.
22. Goldstein M, Pinto B, Marcus B, Lynn H, Jette A, Rakowski W et al. Physician-based physical activity counseling for middle-aged and older adults: a randomized trial. Ann Behav Med 1999; 21: 40-47.
23. Harland J, White M, Drinkwater C, Chinn D, Farr L, Howel D. The Newcastle exercise project: a randomised controlled trial of methods to promote physical activity in primary care. Br Med J 1999; 319: 828-832.
24. Gabhainn S, Kelleher CC, Naughton A, Carter F, Flanagan M, McGrath M. Socio-demographic variations in perspectives on cardiovascular disease and associated risk factors. Health Educ Res 1999; 14: 619-628.
25. Price HC, Dudley C, Barrow B, Kennedy IA, Griffin SJ, Holman RR. Use of focus groups to develop methods to communicate cardiovascular disease risk and potential for risk reduction to people with type2 diabetes. Fam Pract 2009; 26: 351-358.
26. Khaw K, Wareham N, Luben R, Bingham S, Oakes S, Welch A et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). Br Med J 2001; 322: 15-18.
27. Simmons R, Price H, Holman R, Khaw K, Wareham N, Griffin S. Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort. Diabetes Care 2009; 32: 708-712.
28. Price HC. Cardiovascular disease risk estimation: Why, when and how? Diabetes Prim Care 2009; 11: 218-223.
29. Health Development Agency. Public Health Evidence and Practice A Summary of the HDA Delivery Plan for 2004-2005. London: Health Development Agency, 2004.
30. Frijling B, Lobo C, Keus I, Jenks K, Akkermans R, Hulscher M et al. Perceptions of cardiovascular risk among patients with hypertension or diabetes. Patient Educ Couns 2004; 52: 47-53.
31. Atkins C. Translating statistics for use in the clinic. J Gen Intern Med 1997; 12: 626-628.
32. Hollnagel H. Explaining risk factors to patients during a general practice consultation. Conveying group-based epidemiological knowledge to individual patients. Scand J Prim Health Care 1999; 17: 3-5.
33. Ancker J, Senathirajah Y, Kukafka R, Starren J. Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc 2006; 13: 608-618.
34. Edwards A. A Systematic Review of Risk Communication-Improving Effectice Clinical Practice and Research in Primary Care. London: Department of Health, 2007.
35. Riebe D, Blissmer B, Greene G, Caldwell M, Ruggiero L, Stillwell K et al. Long-term maintenance of exercise and healthy eating behaviors in overweight adults. Prev Med 2005; 40: 769-778.
36. Hansson L, Zanchetti A, Carruthers S, Dahlöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
37. Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 2982-2988.